B. Scott

发表

Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

L. Duong, D. Kimmel, T. Cusick, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

L. Duong, Susan Y. Smith, G. Wesolowski, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bioavailability of Alendronate and Vitamin D3 in an Alendronate/Vitamin D3 Combination Tablet

R. Ramakrishnan, J. Wagner, E. Woolf, 2011, Journal of clinical pharmacology.

An Asian viewpoint on the use of vitamin D and calcium in osteoporosis treatment: Physician and patient attitudes and beliefs

S. Sen, S. Chan, B. Scott, 2010, BMC musculoskeletal disorders.

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

L. V. Van Bortel, J. Wagner, K. Lasseter, 2013, British journal of clinical pharmacology.

Evaluation of an experimental urodynamic platform to identify treatment effects: A randomized, placebo‐controlled, crossover study in patients with overactive bladder

R. Railkar, C. Beals, T. Frenkl, 2012, Neurourology and urodynamics.

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

Jason Clark, K. Flaherty, G. Wilding, 2011, Cancer Chemotherapy and Pharmacology.

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

P. Rutgeerts, R. Panaccione, S. Danese, 2014, Gastroenterology.

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.

A. Tolcher, W. Tap, F. Haluska, 2013, Annals of Oncology.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

D. Kiel, M. Sabatine, J. Reginster, 2019, The lancet. Diabetes & endocrinology.

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis

M. Dougados, D. M. van der Heijde, D. Heijde, 2015, Arthritis & rheumatology.

A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia

D. Papanicolaou, J. Chandler, B. Scott, 2013, The journal of nutrition, health & aging.

MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.

D. Papanicolaou, J. Chandler, A. Adunsky, 2011, Archives of gerontology and geriatrics.

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.

R. Chapurlat, S. Bonnick, S. Palacios, 2013, The Journal of clinical endocrinology and metabolism.

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate- a randomized placebo-controlled trial

R. Chapurlat, S. Bonnick, S. Palacios, 2013 .

High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate.

Donald S. Williams, L. Duong, B. Dardzinski, 2013, Bone.

Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey.

Donald S. Williams, L. Duong, T. Hangartner, 2012, Bone.

Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis

A. Santora, A. Pong, B. Langdahl, 2021, Osteoporosis International.

Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis

E. Orwoll, N. Binkley, R. Chapurlat, 2020, Osteoporosis International.

Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.

Donald S. Williams, L. Duong, B. Dardzinski, 2013, Bone.

Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial

Zanchetta, D. Kiel, J. Reginster, 2015 .

Cathepsin K inhibitors prevent bone loss in estrogen‐deficient rabbits

L. Duong, Susan Y. Smith, D. Kimmel, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

P. Alexandersen, C. Benhamou, K. Saag, 2016 .

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies

L. Duong, J. Wagner, D. Panebianco, 2009, Clinical pharmacology and therapeutics.

THURSDAY CONCURRENT SESSION # 1 S-1 . Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis : 5-Year Data from the Extension of the Phase 3 Long-term Odanacatib Fracture Trial ( LOFT )

D. Kiel, J. Manson, J. Cauley, 2016 .

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.

A. Tolcher, W. Tap, F. Haluska, 2013, Annals of Oncology.